Literature DB >> 19807717

'Salience syndrome' replaces 'schizophrenia' in DSM-V and ICD-11: psychiatry's evidence-based entry into the 21st century?

J van Os1.   

Abstract

OBJECTIVE: Japan was the first country to abandon the 19th century term of 'mind-splitting disease' (schizophrenia). Revisions of DSM and ICD are forthcoming. Should the rest of the world follow Japan's example?
METHOD: A comprehensive literature search was carried out in order to review the scientific evidence for the validity, usefulness and acceptability of current concepts of psychotic disorder.
RESULTS: The discussion about re-classifying and renaming schizophrenia and other psychotic disorders is clouded by conceptual confusion. First, it is often misunderstood as a misguided attempt to change societal stigma instead of an attempt to change iatrogenic stigma occasioned by the use of misleading and mystifying terminology. Second, the debate is misunderstood as purely semantic, whereas in actual fact it is about the core concepts underlying psychiatric nosology. Third, it has been suggested that the debate is political. However, solid scientific evidence pointing to the absence of nosological validity of diagnostic categories lies at the heart of the argument. Fourth, there is confusion about what constitutes a syndrome (a group of symptom dimensions that cluster in different combinations in different people and for which one or more underlying diseases may or may not be found) and a disease (a nosologically valid entity with specific causes, symptoms, treatment and course).
CONCLUSION: Scientific evidence favours a syndromal system of classification combining categorical and dimensional representations of psychosis. The concept of 'salience' has the potential to make the public recognize psychosis as relating to an aspect of human mentation and experience that is universal. It is proposed to introduce, analogous to the functional-descriptive term 'Metabolic syndrome', the diagnosis of 'Salience syndrome' to replace all current diagnostic categories of psychotic disorders. Within Salience syndrome, three subcategories may be identified, based on scientific evidence of relatively valid and specific contrasts, named Salience syndrome with affective expression, Salience syndrome with developmental expression and Salience syndrome not otherwise specified.

Entities:  

Mesh:

Year:  2009        PMID: 19807717     DOI: 10.1111/j.1600-0447.2009.01456.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  33 in total

1.  [Schizophrenia: more than just a "disturbance of the integrity of the self"].

Authors:  U Palm; M Lieb
Journal:  Nervenarzt       Date:  2012-03       Impact factor: 1.214

2.  Are antipsychotics antipsychotics?

Authors:  Tilman Steinert; Martin Jandl
Journal:  Psychopharmacology (Berl)       Date:  2010-07-10       Impact factor: 4.530

3.  Toward High Reproducibility and Accountable Heterogeneity in Schizophrenia Research.

Authors:  Peter Kochunov; Paul M Thompson; L Elliot Hong
Journal:  JAMA Psychiatry       Date:  2019-07-01       Impact factor: 21.596

4.  WPA guidance on how to combat stigmatization of psychiatry and psychiatrists.

Authors:  Norman Sartorius; Wolfgang Gaebel; Helen-Rose Cleveland; Heather Stuart; Tsuyoshi Akiyama; Julio Arboleda-Flórez; Anja E Baumann; Oye Gureje; Miguel R Jorge; Marianne Kastrup; Yuriko Suzuki; Allan Tasman
Journal:  World Psychiatry       Date:  2010-10       Impact factor: 49.548

Review 5.  Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.

Authors:  Matcheri S Keshavan; Henry A Nasrallah; Rajiv Tandon
Journal:  Schizophr Res       Date:  2011-02-12       Impact factor: 4.939

6.  Are psychiatrists an endangered species? Observations on internal and external challenges to the profession.

Authors:  Heinz Katschnig
Journal:  World Psychiatry       Date:  2010-02       Impact factor: 49.548

7.  Is late-onset schizophrenia a subtype of schizophrenia?

Authors:  I V Vahia; B W Palmer; C Depp; I Fellows; S Golshan; H C Kraemer; Dilip V Jeste
Journal:  Acta Psychiatr Scand       Date:  2010-11       Impact factor: 6.392

8.  Enhancing Psychosis-Spectrum Nosology Through an International Data Sharing Initiative.

Authors:  Anna R Docherty; Eduardo Fonseca-Pedrero; Martin Debbané; Raymond C K Chan; Richard J Linscott; Katherine G Jonas; David C Cicero; Melissa J Green; Leonard J Simms; Oliver Mason; David Watson; Ulrich Ettinger; Monika Waszczuk; Alexander Rapp; Phillip Grant; Roman Kotov; Colin G DeYoung; Camilo J Ruggero; Nicolas R Eaton; Robert F Krueger; Christopher Patrick; Christopher Hopwood; F Anthony O'Neill; David H Zald; Christopher C Conway; Daniel E Adkins; Irwin D Waldman; Jim van Os; Patrick F Sullivan; John S Anderson; Andrey A Shabalin; Scott R Sponheim; Stephan F Taylor; Rachel G Grazioplene; Silviu A Bacanu; Tim B Bigdeli; Corinna Haenschel; Dolores Malaspina; Diane C Gooding; Kristin Nicodemus; Frauke Schultze-Lutter; Neus Barrantes-Vidal; Christine Mohr; William T Carpenter; Alex S Cohen
Journal:  Schizophr Bull       Date:  2018-10-15       Impact factor: 9.306

9.  The debate about renaming schizophrenia: a new name would not resolve the stigma.

Authors:  W Gaebel; A Kerst
Journal:  Epidemiol Psychiatr Sci       Date:  2018-09-11       Impact factor: 6.892

10.  Reduced dopamine transporter expression in the amygdala of subjects diagnosed with schizophrenia.

Authors:  Matej Markota; Jessica Sin; Harry Pantazopoulos; Rebecca Jonilionis; Sabina Berretta
Journal:  Schizophr Bull       Date:  2014-06-16       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.